GGrantIndex
← Leaderboards

Elizabeth Phillips

University Of Cape Town

Google Scholar ↗PubMed ↗ORCID ↗
$23,551,808
Attributed
$24,375,790
Total exposure
11
Grants
10
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $4.9M · FY2015–25
$5M$3.8M$2.5M$1.3M$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$37,350,174 · 12

By mechanism

P50$16,249,041 · 2
U01$15,479,064 · 1
R01$4,762,514 · 2
R21$434,500 · 1
R13$219,679 · 5
R34$205,376 · 1

Top collaborators

Most similar at University Of Cape Town

Same institution · by research overlap

Others in their field

Top investigators on “Mediating”

Research focus

MediatingPharmaceutical PreparationsMorbidity - Disease RateMortalityAllelesPhenotypeStevens-Johnson SyndromeToxic Epidermal NecrolysisPreventionGeneticCellsCarbamazepineScreeningPreventSamplingDrug ToleranceImmunologicsSkinTranslationsImmuneLifeAffectDrug UsageAdverse Drug Reaction

Grant awards (37)

Immune-mediated adverse drug reactions to HIV and TB treatments in South Africa: predict, prevent and improve long-term outcomes (IMARI SA study)$308,214
R01 · FY2025 · AI
SCAR 2025: Stronger Together$60,000
R13 · FY2025 · AR · contact PI
NATIENS: A Phase III Randomized Double Blinded Study to Determine the Mechanisms and Optimal Management of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis$1
U01 · FY2025 · AI · contact PI
NATIENS: A Phase III Randomized Double Blinded Study to Determine the Mechanisms and Optimal Management of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis$1,300,966
U01 · FY2024 · AI · contact PI
Immune-mediated adverse drug reactions to HIV and TB treatments in South Africa: predict, prevent and improve long-term outcomes (IMARI SA study)$319,378
R01 · FY2024 · AI
NATIENS: A Phase III Randomized Double Blinded Study to Determine the Mechanisms and Optimal Management of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis$3,507,424
U01 · FY2023 · AI · contact PI
Immune-mediated adverse drug reactions to HIV and TB treatments in South Africa: predict, prevent and improve long-term outcomes (IMARI SA study)$330,076
R01 · FY2023 · AI
Stevens Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN) 2023$45,133
R13 · FY2023 · AR · contact PI
NATIENS: A Phase III Randomized Double Blinded Study to Determine the Mechanisms and Optimal Management of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis$3,316,841
U01 · FY2022 · AI · contact PI
Genetic risk and long-term outcomes associated with Drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in survivors$799,660
R01 · FY2022 · HG · contact PI
NATIENS: A Phase III Randomized Double Blinded Study to Determine the Mechanisms and Optimal Management of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis$3,535,017
U01 · FY2021 · AI · contact PI
Genetic risk and long-term outcomes associated with Drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in survivors$816,270
R01 · FY2021 · HG · contact PI
Immune-mediated adverse drug reactions to HIV and TB treatments in South Africa: predict, prevent and improve long-term outcomes (IMARI SA study)$340,382
R01 · FY2021 · AI
Stevens-Johnson syndrome/toxic epidermal necrolysis 2021: Collaboration, Innovation and Community$32,546
R13 · FY2021 · AR · contact PI
NATIENS: A Phase III Randomized Double Blinded Study to Determine the Mechanisms and Optimal Management of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis$3,818,815
U01 · FY2020 · AI · contact PI
Genetic risk and long-term outcomes associated with Drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in survivors$755,862
R01 · FY2020 · HG · contact PI
Immune-mediated adverse drug reactions to HIV and TB treatments in South Africa: predict, prevent and improve long-term outcomes (IMARI SA study)$349,915
R01 · FY2020 · AI
Improving Prediction of Drug Action$2,616,904
P50 · FY2019 · GM
Genetic risk and long-term outcomes associated with Drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in survivors$742,757
R01 · FY2019 · HG · contact PI
Understanding and preventing HLA-associated drug reactions$546,253
P50 · FY2019 · GM · contact PI
Single Cell definition of pathogenic T cells in Drug-induced Stevens-Johnson-Syndrome/Toxic epidermal necrolysis$197,500
R21 · FY2019 · AI · contact PI
Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis 2019: From Science to Translation$39,000
R13 · FY2019 · AR · contact PI
Improving Prediction of Drug Action$2,592,271
P50 · FY2018 · GM
Understanding and preventing HLA-associated drug reactions$559,683
P50 · FY2018 · GM · contact PI
Single Cell definition of pathogenic T cells in Drug-induced Stevens-Johnson-Syndrome/Toxic epidermal necrolysis$237,000
R21 · FY2018 · AI · contact PI
NATIENS: A Phase III Randomized Study to Determine the Mechanisms and Optimal Management of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis$205,376
R34 · FY2018 · AI · contact PI
Improving Prediction of Drug Action$2,584,732
P50 · FY2017 · GM
Understanding and preventing HLA-associated drug reactions$611,735
P50 · FY2017 · GM · contact PI
Stevens-Johnson Syndrome/Toxic Epidural Necrolysis 2017: Building Multidisciplinary Networks to Drive Science and Translation$43,000
R13 · FY2017 · AR · contact PI
Improving Prediction of Drug Action$2,564,195
P50 · FY2016 · GM
Understanding and preventing HLA-associated drug reactions$607,747
P50 · FY2016 · GM · contact PI
Improving Prediction of Drug Action$44,613
P50 · FY2016 · GM
Improving Prediction of Drug Action$15,769
P50 · FY2016 · GM
Improving Prediction of Drug Action$1,377,542
P50 · FY2015 · GM
Improving Prediction of Drug Action$1,178,358
P50 · FY2015 · GM
Understanding and preventing HLA-associated drug reactions$625,456
P50 · FY2015 · GM · contact PI
Understanding and preventing HLA-associated drug reactions$323,783
P50 · FY2015 · GM · contact PI